Lung cancer is one of the most common cancer types worldwide and the leading cause of cancer-related deaths1. Screening for lung cancer with low-dose computed tomography (CT) has therefore been suggested to diagnose patients before symptoms occur2. Low stages are often detected as small lung lesions or nodules. From one of the largest screening studies conducted in the Netherlands, we know that these lesions are often located in the outer 2/3 of the lung parenchyma and are thereby defined as peripheral lung cancers3,4. To determine whether a lesion is malignant, a tissue sample is required. This can be obtained in several different ways such as surgical excision biopsy, trans-thoracic needle biopsy, or endoscopic with a bronchoscope5,6, the latter having a lower risk of complications compared to surgery and the trans-thoracic approach and a preferable method for diagnosing an increasing elderly population with considerable comorbidities. The diagnostic yield, however, is still lower than the other modalities5.
The bronchoscope allows for visual inspection of the trachea and the main bronchi, but when the bronchi branch into segments and subsegments, locating one small lesion is comparable to finding a needle in a haystack. Therefore, several additional modalities have been developed to guide the bronchoscope to the lesion and confirm the location of a tumor before tissue sampling7. The purpose of these modalities is to increase the diagnostic yield of endoscopic tissue sampling and expand the reach of the bronchoscope towards the pleura, where trans-thoracic needle biopsies are otherwise performed8,9.
Fluoroscopy using a C-arm provides a 2D X-ray image of the thorax during bronchoscopy. It can be used to visualize the position of the bronchoscope and the forceps for trans-bronchial biopsies (TBB) to avoid sampling the pleura and the vascular structures of the intermediate 1/3 of the lung parenchyma when performing random TBBs. When diagnosing lung cancer, fluoroscopy can be used to guide the scope to an "approximate" location of the lesion. Lesions are usually visible on fluoroscopy when the diameter is around 2-2.5 cm or above10. The drawback of fluoroscopy is the 2D image properties, which makes it impossible to know whether the scope is in front, behind, or the center of the lesion11. However, fluoroscopy is also used to confirm that the biopsy tools are in the desired location during sampling if the presence of a tumor has been confirmed with radial endobronchial ultrasound (rEBUS)12.
rEBUS was first described in 1992 by Hürter et al. and is increasingly used in diagnostic workup of peripheral lung lesions13. This modality utilizes the fact that the air-filled lung tissue does not conduct ultrasound waves, whereas denser tissue will appear as a consolidation when scanned using an ultrasound probe. rEBUS is comprised of a circular and rotating ultrasound probe, an ultrasound driving unit, and a guide sheath used to protect the probe while ensuring the correct position of the biopsy tools14. rEBUS can be used on its own or together with other modalities such as electromagnetic navigation bronchoscopy (ENB)15,16,17.
ENB is used to locate a peripheral lung lesion18. The system uses a software program and a CT scan from the patient. A virtual model of the patient´s airways is generated from the CT scan and the operator designs a route from the trachea to the lesion. An electromagnetic field is then created around the patient´s chest and the software synchronizes this field with the virtual field generated from the CT scan, thus assisting the operator to follow the preplanned route during the bronchoscopy, similar to Global Positioning System technology. ENB does not provide real-time confirmation of tumor location. ENB can be combined with fluoroscopy and rEBUS19,20. Virtual Navigation Bronchoscopy (VBN) is the predecessor to ENB and consists of software for creating the virtual model of the bronchial tree along with a route to the lesion. The system does not include real-time navigation, but the route can be displayed during the bronchoscopy21,22. New systems incorporate VBN with fluoroscopy but the use of VBN will not be described in the following protocol23.
ENB systems
Currently, two companies produce systems for ENB, the SPiN system from Olympus and the superDimension system and the ILLUMISITE both sold by Medtronic. The protocol will describe a procedure using the superDimension system, which currently has the most publications. However many steps of the procedure are interchangeable.
The following protocol will describe how to perform rEBUS under fluoroscopy and ENB + rEBUS under fluoroscopy in a clinical setting. The procedures can easily be performed under conscious sedation and general anesthesia. The protocol will not describe any methods for sedation. In the discussion section, the pros and cons of each procedure will be presented.